Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total transaction of $4,518,200.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $52,037,916.68. The trade was a 7.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Thermo Fisher Scientific Stock Up 1.4%
Thermo Fisher Scientific stock traded up $6.15 during mid-day trading on Thursday, reaching $455.09. The stock had a trading volume of 1,490,140 shares, compared to its average volume of 3,299,804. The company has a market capitalization of $171.85 billion, a price-to-earnings ratio of 26.32, a PEG ratio of 2.40 and a beta of 0.74. The company has a 50-day moving average price of $424.58 and a two-hundred day moving average price of $465.66. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the previous year, the firm earned $5.37 EPS. Thermo Fisher Scientific's revenue was up 2.9% on a year-over-year basis. On average, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.
Thermo Fisher Scientific Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.
Wall Street Analyst Weigh In
Several analysts have recently commented on the stock. Argus decreased their price target on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research note on Tuesday, April 29th. Evercore ISI cut their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Barclays increased their target price on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a report on Thursday, July 24th. Wells Fargo & Company dropped their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a report on Thursday, July 24th. Finally, Raymond James Financial restated an "outperform" rating and set a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Six equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and an average target price of $593.00.
Check Out Our Latest Stock Analysis on Thermo Fisher Scientific
Institutional Trading of Thermo Fisher Scientific
Institutional investors and hedge funds have recently made changes to their positions in the business. Brighton Jones LLC grew its stake in shares of Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock worth $2,293,000 after acquiring an additional 988 shares during the last quarter. Revolve Wealth Partners LLC raised its stake in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares during the last quarter. Bank Pictet & Cie Europe AG increased its holdings in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock worth $79,677,000 after buying an additional 461 shares during the last quarter. FIL Ltd grew its holdings in shares of Thermo Fisher Scientific by 58.5% during the 4th quarter. FIL Ltd now owns 347,139 shares of the medical research company's stock worth $180,592,000 after purchasing an additional 128,095 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in Thermo Fisher Scientific by 270.5% during the 4th quarter. Renaissance Technologies LLC now owns 181,344 shares of the medical research company's stock valued at $94,341,000 after acquiring an additional 132,393 shares during the period. 89.23% of the stock is currently owned by institutional investors.
Thermo Fisher Scientific Company Profile
(
Get Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
